Concepedia
Statistics
Publications
5
Citations
853
H-Index
Active since
2004
Affiliations
Inserm(Current)
Institut de génétique et de biologie moléculaire et cellulaire
Centre National de la Recherche Scientifique
Novartis (United States)
Novartis (Switzerland)
Emilie Voltz is an author at Inserm specializing in molecular oncology, oncology, and signal transduction in cancer.
Publications per year
2004–2024
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Angela Nebbioso, Nicole Clarke, Emilie Voltz et al. · Nature Medicine · 2004 · 620 citations
Medicine, Oncology, Pharmacology +13
Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL
Nicole Clarke, Ana M. Jiménez‐Lara, Emilie Voltz et al. · The EMBO Journal · 2004 · 140 citations · Full text
Life Sciences, Cancer Biology, Oncology +16
First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor
Ewa Gatlik, Beata Mehes, Emilie Voltz et al. · Clinical and Translational Science · 2024 · 52 citations · Full text
Pharmacy, Pharmacokinetics, Pharmacology +13
Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results
Lawrence Charnas, Emilie Voltz, C. Pfister et al. · Neuromuscular Disorders · 2017 · 22 citations
Medicine, Neurology, Neuroscience +6
Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Per Lund, Irina Kotova, Valérie Kedinger et al. · Molecular Cancer Therapeutics · 2011 · 19 citations · Full text
Life Sciences, Molecular Biology, Oncology +17
1–5 of 5